Fig. 5

AD-tau-injected 5XFAD mice treated with PLX3397 had greatly reduced APP-positive dystrophic processes and AT8-positive NP tau. a Representative 22C11-positive APP IF images of a control (CTR) and PLX3397-treated (PLX) AD-tau-injected 5XFAD mouse, showing the annotation of the cortical region and selection of APP-positive dystrophic processes with exclusion of APP-positive neuronal soma (see insert). b Quantification of cortical APP-positive dystrophic processes. One female PLX3397-treated mouse was excluded from the analysis because useable brain sections were unavailable. c Representative images of AT8-positive tau in control (CTR) and PLX3397-treated (PLX) AD-tau-injected 5XFAD mice, with quantification of d cortical and e subiculum NP tau pathology. The inset in C is a dual-stained image from the subiculum showing that AT8 (green) staining is found in processes that are closely associated with Aβ plaques (NAB228; violet). Scale bars represent 0.4 mm